Longevity is shifting from lifespan claims toward clinical proof. A 53,018-person proteomic score, naked-mole-rat gene transfer in mice and major biotech financings point to an investable stack built on validation, endpoints, manufacturing, regulation, safety and payer relevance—not hype alone.